Mibi

Technetium (99mTc) sestamibi, the active ingredient in Mibi, is a radiopharmaceutical presented as an injection for intravenous use. It is employed to evaluate myocardial blood flow and detect coronary artery disease in patients undergoing cardiac assessment, including stress testing and viability studies.

GNH USA supplies Mibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic centres and cardiac imaging facilities worldwide. The product meets EU regulatory standards and is distributed under strict quality‑control procedures.

Mibi is used in cardiac imaging to assess myocardial perfusion and related conditions. - Myocardial perfusion imaging: enables visualization of blood flow to detect coronary artery disease. - Stress testing: assesses myocardial blood flow response during pharmacologic or exercise stress. - Viability assessment: helps differentiate viable myocardium from scar tissue after infarction.

Adverse reactions to Mibi are generally related to the radiopharmaceutical nature of the product and its intravenous administration.

Common Side Effects: - Nausea: mild to moderate discomfort shortly after injection. - Vomiting: occasional emesis within the first hour. - Headache: transient headache reported by some patients. - Dizziness or light‑headedness: brief sensations of imbalance. - Flushing or warmth: mild skin sensation at the injection site. - Transient hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Allergic reaction: rash, urticaria, or anaphylaxis. - Severe hypotension: marked blood pressure decline requiring intervention. - Cardiac arrhythmia: abnormal heart rhythm observed during stress testing. - Radiation‑induced skin injury: localized erythema at the injection site. - Radiation‑related malignancy: theoretical risk of long‑term cancer development. - Pulmonary embolism: rare occurrence of embolic events.

When using Mibi, several precautions should be observed to ensure patient safety and optimal imaging results. - Patient assessment: evaluate renal function and cardiac status before administration. - Pregnancy: avoid use unless essential, as fetal radiation exposure is unknown. - Breastfeeding: discontinue breastfeeding for an appropriate period after injection. - Concomitant drugs: consider effects of agents that alter myocardial blood flow, such as beta‑blockers or nitrates. - Radiation safety: limit exposure to staff and other patients by following shielding protocols. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mibi may interact with other medications or substances that influence myocardial blood flow or radiation exposure.

Major Interactions (Avoid): - Beta‑blockers: can blunt stress‑induced perfusion changes, affecting image interpretation. - Calcium channel blockers: may alter coronary vasodilation and tracer distribution. - Nitrates: can modify myocardial blood flow, leading to inaccurate perfusion assessment. - Dipyridamole: concurrent use interferes with pharmacologic stress protocols. - Other radiopharmaceuticals: simultaneous administration can cause competitive uptake.

Moderate Interactions (Monitor Closely): - Caffeine: may reduce vasodilator response during stress testing. - Nicotine or tobacco use: can affect coronary tone and tracer uptake. - Thyroid hormones: altered metabolism may influence tracer clearance. - Antihistamines: may mask mild allergic reactions. - Contrast agents: timing should be spaced to avoid imaging interference.